OptoSeeker Biotech, a pioneer in advanced life science instrumentation, today announced its inclusion in the prestigious "2025 Venture 50" China Life Sciences List. Released jointly by Zero2IPO Group and ChinaVenture, the list recognizes OptoSeeker for its robust technological capabilities and exceptional commercial potential, selecting the company from a competitive pool of tens of thousands of enterprises nationwide.
A Benchmark for High-Growth Innovation For over two decades, the "Venture 50" has served as the definitive bellwether for high-growth investment targets in China, engaging more than 81,000 technology enterprises since its inception. The 2025 selection process involved rigorous multi-round screenings by hundreds of top-tier investment institutions, identifying industry benchmarks across Artificial Intelligence, Hard Tech, and Life Sciences.
OptoSeeker’s inclusion underscores the capital market’s recognition of its innovation value and marks the company's emergence as a key player in the high-end life science instrumentation sector. Amidst a complex industry landscape characterized by both capital constraints and explosive technical growth, this recognition highlights OptoSeeker’s resilience and clear strategic direction.
Driven by Core Technology OptoSeeker’s success is powered by its relentless focus on deep-tech R&D. The company has built a proprietary technology stack integrating optoelectronic tweezers, microfluidics, antibody discovery, and gene editing capabilities.
Its flagship OptoBot® 1000 Series High-Throughput Single-Cell Optofluidic Sorting System provides a fully autonomous, closed-loop workflow covering "screening, sequencing, and analysis". This platform addresses critical bottlenecks in biopharmaceutical R&D, significantly shortening antibody screening timelines and reducing costs for cell and gene therapy (CGT) development. Additionally, OptoSeeker has expanded its portfolio with the OptoNeuroBot® Patterned Illuminator and the DropletBot® Digital Microfluidic Platform.
Looking Ahead "2025 is a pivotal year defined by the release of policy incentives and accelerated technological iteration," the company stated. "This honor reflects the dedication of our team and the trust of our partners and investors. Moving forward, we will continue to prioritize the iteration of our core products and the translation of scientific achievements into commercial reality, contributing 'OptoSeeker strength' to the global biomedical innovation ecosystem".
About OptoSeeker Biotech Founded in 2023, OptoSeeker Biotech is dedicated to developing cutting-edge life science instruments that accelerate biological research. The company’s OptoBot® product family deeply integrates optofluidics, biochips, and protein tagging technologies to enable fully automated single-cell workflows—from loading and culture to characterization and sorting.
By delivering high-throughput, high-precision tools, OptoSeeker empowers discoveries in antibody drug development, cell line development, and CGT.
For more information, please visit: https://www.optoseeker.com/en
